Lung cancer kills more Americans yearly than any other neoplastic process. Mortality rates have changed little over the past several decades, despite improvements in surgical techniques, radiation therapy and chemotherapy. The identi®cation of mutations in oncogenes and tumor suppressor genes in human lung tumor specimens, including K-ras, p53, p16
Introduction
Lung cancer is the third most common non-cutaneous cancer and is the leading cause of death from cancer in the United States, with 171 500 new cases and 165 600 deaths projected for 1998 (Landis et al., 1998) . Lung cancer cases are sporadic, and tobacco product usage is the strongest risk factor identi®ed to date: 80 ± 90% of all patients are past or current smokers and 10% of all smokers will develop lung cancer after a latency period of years to decades (Shopland et al., 1991) . Primary prevention through smoking cessation is likely responsible for the recent stabilization of lung cancer incidence and mortality in men; however, current smoking trends among teenagers in the US and adults worldwide ensure that this disease will remain a national and global health pandemic (MMWR, 1996; Lopez, 1999) .
The high case : fatality ratio observed in lung cancer is attributed to the often advanced stage of disease at time of diagnosis, a poor response to therapy, and the aggressive biologic nature of lung cancer. Speci®c genetic mutations induced by carcinogens in tobacco smoke may explain the natural history and treatment refractoriness of lung cancer. These mutations are also being pursued as potential early detection screening markers.
Murine models of lung cancer may expedite the dissection of the molecular pathways involved in the development of lung cancer, and allow the testing of novel therapeutic approaches and screening strategies. Current mouse models for lung cancer include strains susceptible to spontaneous and chemicallyinduced lung tumor development, and several transgenic mouse strains which express viral and cellular oncogenes. Importantly, many of the same genetic mutations observed in human lung tumors are also present in murine lung tumors, including mutations of K-ras, p16 INK4a , and p53. Furthermore, crosses between susceptible and resistant inbred mouse strains have allowed the mapping of modifier loci for lung tumor development. However, murine lung tumors are predominantly early stage lesions which display limited histologic variation. Here, we review the progress of this ®eld and suggest new approaches.
Human lung cancer: clinical and pathologic considerations
Patients come to medical attention due to either an incidental chest X-ray ®nding or a speci®c complaint. Presenting symptoms include those caused by local mass eects of the tumor, such as cough and diculty breathing; symptoms due to distant metastases such as seizures and bone pain; systemic symptoms such as anorexia, weight loss, and fatigue; and paraneoplastic syndromes that result in electrolyte disturbances and blood clotting disorders. The initial approach to patients includes a tissue biopsy for de®nitive pathologic diagnosis, and determination of the extent of disease for formulation of the clinical prognosis (Nesbitt et al., 1997) .
Epithelial neoplasms of the lung are pathologically described as either non-small cell lung carcinoma (NSCLC) or small cell carcinoma (SCLC), and this distinction is important clinically due to their dierent responses to therapy. The three main types of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma (WHO, 1982) . Adenocarcinoma represents 30 ± 40% of lung cancers, often originates in peripheral portions of the lung, and is further classi®ed into three subgroups: acinar adenocarcinoma, which is overtly glandular in appearance and shows abundant mucin production; papillary adenocarcinoma, which has a frond-like growth pattern; and bronchiolo-alveolar carcinoma (BAC), a well-differentiated tumor that grows along pre-existing alveolar walls. Squamous cell carcinoma constitutes 20 ± 25% of lung cancers, tends to arise centrally from in situ carcinoma of the larger bronchi, and is characterized histologically by intercellular bridges and overt keratinization. Large cell carcinoma accounts for 15 ± 20% of lung cancers, occurs throughout the lung, and is characterized by the lack of glandular or squamous dierentiation and the presence of large cells with large nuclei and prominent nucleoli. Small cell carcinoma (SCLC) represents 20% of lung cancers, arises centrally, metastasizes frequently, and is characterized by intermediate cell size, speci®c neuroendocrine nuclear features such as the lack of nucleoli, and very high mitotic and apoptotic rates. Human lung tumor specimens are often histologically heterogeneous, which suggests the presence of a common precursor cell or transitions between dierent histologic types (Roggli et al., 1985; Mabry et al., 1988) . The pathway of histologic progression in lung cancer is poorly understood due to the scarcity of pre-invasive lesions for analysis, although potential candidates include squamous metaplasia and carcinoma-in-situ detected in some patients prior to or concomittant with the diagnosis of squamous cell carcinoma (Auerbach et al., 1961) , and a lesion termed`atypical adenomatous hyperplasia' that is identi®ed occasionally in the lungs of smokers without lung cancer and frequently in tissue adjacent to bronchiolo-alveolar carcinoma specimens (Nakanishi, 1990) .
The extent or`stage' of disease is determined from the results of radiological exams such as computed tomography imaging, and additional surgical procedures including lymph node biopsy. Staging is used to stratify lung cancer patients into treatment categories and to predict survival. À Tumor-Node-Metastasis' (TNM) staging system is used for patients with NSCLC, based on the size and location of the primary tumor (T), the location of involved lymph nodes (N), and the presence of metastatic lesions (M). Patients with TNM stages 1 ± 3 are candidates for combined modality therapy including surgery, chemotherapy, and radiation therapy; however, the 30 ± 50% of patients that present with metastatic or TNM stage 4 NSCLC are generally not treated with surgical resections, other than in the context of palliation, as this has not been shown to provide a survival advantage. Survival rates for NSCLC are most clearly predicted by the stage at the time of diagnosis, with 40 ± 60% of stage 1 patients, 20 ± 30% of stage 2 patients, 5 ± 10% of stage 3 patients, and less than 5% of stage 4 patients being alive 5 years after treatment (Ries, 1994) . Subtypes of NSCLC that are matched for disease stage tend to respond similarly to systemic therapy. The staging system for SCLC diers from the TNM system of NSCLC, and consists simply of limited stage and extensive stage disease. The minority of patients that present with limited stage disease SCLC are generally treated with high dose chemotherapy and radiation therapy; whereas palliative chemoradiotherapy is used for extensive stage disease. SCLC tumors often respond dramatically to initial treatment, but relapse quickly with therapyresistant disease. SCLC is not treated with surgical excision due to the lack of eect of surgery on the course of disease. The 5-year survival for SCLC is less than 3% for all cases, with only a slight improvement for limited stage disease. Treatment of both NSCLC and SCLC can result in symptomatic improvements for patients, and some studies have shown prolonged survival for selected groups of patients (Nesbitt et al., 1997) .
Human lung cancer: molecular characterization
Lung cancer occurs in the setting of multiple chromosomal abnormalities and genetic mutations found throughout the airways and alveoli in smokers (Wistuba et al., 1997) .`Field cancerization' is a term used to describe this multifocal process, and the occurrence of synchronous and metachronous tumors in some lung cancer patients is easily understood in this context (Sozzi et al., 1995) . These molecular changes can persist for many years after smoking cessation, in accordance with the long latency period often observed prior to the development of lung cancer (Wistuba et al., 1997; Mao et al., 1997) .
DNA adduct formation and direct oxidative damage by components in tobacco smoke provides a molecular mechanism for the origin of these mutations. For example, polyaromatic hydrocarbons such as benzo(a)pyrene (BAP) are present at high levels in tobacco smoke and are metabolized in lung tissues to reactive epoxide intermediates by speci®c cytochrome p450 enzymes. These epoxide intermediates are either detoxi®ed by the cell or react with deoxyguanine to form a covalent adduct. DNA synthesis is impaired by these bulky adducts, resulting in G-to-T transversions which are prevalent in tobacco-related tumors (Harvey, 1991) . Another DNA-modifying chemical in tobacco smoke is the nitrosamine metabolite of nicotine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), which reacts with DNA to form O 6 -methylguanine adducts, and ultimately causing G-to-A transitions and G-to-T transversions (Ronai et al., 1993) .
Lung cancer specimens demonstrate multiple molecular alterations, including activation and overexpression of oncogenes, deletion and reduced expression of tumor suppressor genes, and cytogenetic abnormalities. The pattern of genetic changes found in primary lung tumors are characteristic of, but not speci®c for, either NSCLC or SCLC. NSCLC specimens contain activating K-ras mutations in 20 ± 50% of the tumors (Rodenhuis and Slebos et al., 1990; Mills et al., 1995) ; 50% have deletions or mutations of p53 (Kondo et al., 1992; Mitsudomi et al., 1992) ; 60% show deletion or reduced expression of p16
INK4a (Kamb et al., 1994; Okamoto et al., 1994 Okamoto et al., , 1995 Merlo et al., 1995; Shapiro et al., 1995; Xiao et al., 1995) ; and up to 30% show deletion or reduced expression of Rb (Xu et al., 1991; Reissmann et al., 1993) . SCLC specimens demonstrate overexpression of the myc family of protooncogenes due to gene ampli®cation in 10 ± 40% of the tumors (Little et al., 1983; Johnson et al., 1987; Takahashi et al., 1989; Noguchi et al., 1990) ; 80% have p53 mutations or deletions Hensel et al., 1991; Takahashi et al., 1991; Sameshima et al., 1992) ; and 90% have deletions of Rb (Yokota et al., 1988; Hensel et al., 1990) . Chromosome 3p deletions, which occur at a chromosomal fragile site and often include the FHIT gene, are found in 50% of NSCLC and 90% of SCLC primary tumors (Brauch et al., 1987; Sozzi et al., 1996) . Additional observations include cyclin D1 overexpression in a majority of NSCLC cell lines, which may result in Rb inactivation (Schauer et al., 1994) ; overexpression of the tyrosine kinase growth factor receptor cerbB2/neu in 10 ± 30% of NSCLC tumors and cell lines, which correlates with a worse prognosis Weiner et al., 1990) ; and overexpression of bcl-2 in 10 ± 25% of NSCLC specimens, with increased survival for the subset of squamous cell carcinoma patients that had bcl-2 increased expression (Pezzela et al., 1993) . Further investigations of the numerous chromosomal abnormalities found in SCLC and NSCLC, such as chromosomal gains at 1p, 3q, 5p, 7p, 8q, 12p and 19q, and chromosomal losses and loss of heterozygosity (LOH) at 1p, 1q,  3p, 5p, 5q, 8p, 9p, 10q, 13q, 15q, 17p and 18q may reveal the existence of additional oncogenes and tumor suppressors, respectively, that are involved in lung tumorigenesis (Shiseki et al., 1996; Balsara et al., 1997; Mertens et al., 1997; Petersen et al., 1997; Virmani et al., 1998) . Molecular abnormalities identi®ed in lung tumors are the basis for the development of screening tests for lung cancer, such as the examination of sputum from smokers for Kras and p53 mutations (Mao et al., 1994) .
Murine lung cancer: pathologic and molecular characterization
In contrast to human lung cancer, the majority of murine lung tumors are histologically early lesions such as hyperplasias and adenomas, which may originate from either Clara cells or alveolar type 2 cells that line alveoli (Thaete and Malkinson, 1991) . The more advanced tumors resemble papillary and bronchioloalveolar adenocarcinomas, and appear to metastasize infrequently (Stewart et al., 1979; Dixon et al., 1991; Foley et al., 1991) .
Several molecular alterations identi®ed in these lesions are shared with human lung carcinoma specimens. K-ras activating mutations are found in 80 ± 90% of the tumors, including early hyperplastic lesions (You et al., 1989) . LOH studies demonstrated the consistent loss of regions of mouse chromosome 4 in some lung adenocarcinoma lines, and further investigations demonstrated that this region was syntenic with human 9p21-22, containing murine p16
INK4a Herzog et al., 1994) . p16
INK4a deletion or reduced expression through promoter methylation has been demonstrated in 50% of the adenocarcinomas, but not in earlier lesions (Herzog et al., 1996) . p53 mutations are found infrequently, and only in more advanced lesions (Horio et al., 1996) . In murine lung adenocarcinoma specimens, LOH at chromosomes 4, 11 and 14, known to involve p16
INK4a
, p53 and Rb, respectively, has been described . The murine Fhit gene was cloned and mapped to an aphidicolininducible fragile site on chromosome 14 (Pekarsky et al., 1998; Glover et al., 1998) . Chromosomal deletions and truncated mRNA products involving Fhit were noted in multiple primary murine lung tumors and lung cancer cell lines, consistent with the analysis of FHIT in human cancer (Sozzi et al., 1996) . Gene disruption experiments are underway to further examine the in vivo role of Fhit in tumorigenesis and development (Pekarsky et al., 1998) .
Murine lung cancer models: spontaneous and treatment-induced
Spontaneous lung cancer develops in approximately 3% of wild mice and has a strain-dependent incidence in inbred mice (Lynch, 1926; Shimkin, 1995) . The strains of Mus musculus most sensitive to the spontaneous development of lung tumors include A/J and SWR; strains with intermediate sensitivity include BALB/c and O20; relatively resistant strains include CBA and C3H; and the most resistant strains include DBA and C57BL/6. The sensitive A/J strain has a 100% prevalence of spontaneous lung tumors by 18 ± 24 months of age, with the earliest onset of tumors at 3 ± 4 months (Shimkin, 1955) . The propensity of these strains to develop lung tumors strongly correlates with a polymorphism in the second intron of K-ras (You et al., 1992) . The polymorphism is a 37 nucleotide intronic sequence that is tandemly duplicated in resistant strains and is present as a single copy in sensitive strains; this polymorphism appears to confer dierent nuclear protein binding abilities that may in¯uence gene expression (Chen et al., 1994a) . Furthermore, in the F1 progeny of a cross between the sensitive A/J strain and the resistant C3H strain, the A/J allele of K-ras is expressed at higher levels than the C3H allele and is selectively mutated in lung tumors (Chen et al., 1994b) .
Mice susceptible to spontaneous lung tumors are also often sensitive to chemically-induced lung cancer. This observation became the basis for a quantitative carcinogenicity bioassay (Andervont and Shimkin, 1940; Shimkin, 1940; Shimkin and Stoner, 1975) , and a screening system for chemopreventative agents (Wattenberg and Leong, 1970; Stoner et al., 1993) . A wide variety of chemicals can stimulate murine lung tumorigenesis with a range of potencies, including urethane, metals, a¯atoxin, and constituents of tobacco smoke such as polyaromatic hydrocarbons and nitrosamines (Shimkin and Stoner, 1975; Stoner, 1991; Hecht et al., 1989; Kim and Lee, 1996) . These agents can act as initiators and/or promoters of pulmonary tumorigenesis by accelerating tumor onset and increasing tumor multiplicity. Interestingly, tobacco smoke is only weakly carcinogenic to mice when compared to treatment with single agents present in tobacco smoke, suggesting a complex interaction between the multiple components present in tobacco smoke and pulmonary epithelial cells (Witschi, 1998) . Furthermore, the actual carcinogenic agent in tobacco smoke was recently questioned by a report demonstrating that the gas phase of tobacco smoke, which has markedly reduced levels of NNK and BAP, was nonetheless able to induce lung tumorigenesis in mice (Witschi et al., 1997) .
Transgenic mouse lung cancer models
Many strains of transgenic mice have been generated that develop pulmonary adenomas and adenocarcinomas. For example, transgenic mice that express SV40 Large T antigen under the control of promoters speci®c to pulmonary epithelium, such as human surfactant protein C (SPC) (Wikenheiser et al., 1992) , and rabbit uteroglobin (Sandmoller et al., 1995) develop multiple lung tumors that cause early death. In addition, transgenic mice expressing activated forms of H-ras from either the SV40 early promoter (Suda et al., 1987) or the albumin promoter and enhancer , and proto-oncogenic H-ras under control of its own promoter (Saitoh et al., 1990 ) have a high incidence of lung tumors. Finally, mice transgenic for mutant p53 develop lung tumors, possibly due to dominant-negative functions of this transgene (Lavigueur et al., 1989) .
Mice have been created that have germline disruptions of three tumor suppressor genes mutated in human lung cancer: p53, p16
INK4a
, and Rb. Mice heterozygous and homozygous de®cient for p53 (Donehower et al., 1992; Jacks et al., 1994) and p16
INK4a (Serrano et al., 1996) are viable and have shortened lifespans due to the predominant occurrence of lymphomas and a variety of sarcomas. Mice heterozygous de®cient for Rb have shortened lifespans due to the growth of pituitary tumors, and homozygous Rb de®ciency causes embryonic death (Jacks et al., 1992; Lee et al., 1992; Clarke et al., 1992) . Although the incidence of lung cancer is not increased in the p53, p16
INK4a and Rb mutant mice, one group demonstrated bronchiolar neuroendocrine cell hyperplasia in mice homozygous de®cient for p53 and heterozygous de®cient for Rb . A similar histological ®nding has been noted in some patients with benign obstructive respiratory disorders and in a few with carcinoid tumors of the lung, an uncommon human pulmonary epithelial malignancy which rarely metastasizes (D' Agati and Perzin, 1985; Aguayo et al., 1992) .
Modi®ers of murine lung tumorigenesis
Genetic loci which modify lung tumorigenesis have been identi®ed through the evaluation of crosses between dierent inbred strains or species of mice. Treatment with urethane post-natally or N-ethyl-Nnitrosourea (ENU) pre-natally is often performed to accelerate tumorigenesis and expedite the analysis. Initial crosses between the sensitive strain A/J and the resistant strain C57BL/6J suggested the presence of at least three loci which positively in¯uenced the formation of pulmonary adenomas (Malkinson et al., 1985) . Further experimentation, involving a cross between strain A/J and resistant strain C3H/He and the analysis of F2 progeny, clari®ed this model by ®rmly establishing the presence of a major susceptibility locus for pulmonary adenoma formation, termed Pas1, at a distal region on chromosome 6 (Gariboldi et al., 1993) . Pas1 was initially noted to map closely to the murine K-ras gene, and further studies using recombinant inbred species of mice have re®ned and strengthened this linkage (Lin et al., 1998) . Additional Pas loci have been mapped to chromosomes 9, 17, and 19 (Devereux et al., 1994; Festing et al., 1994) .
Loci which counteract Pas1 have also been identi®ed. An interspecies cross between Mus musculus A/J strain and Mus spretus was performed, and the F1 progeny were further crossed to adenoma-resistant C57BL/6 to produce ASB mice. As expected, 50% of the ASB mice developed lung tumors, and all susceptible mice contained the A/J locus Pas1.
However, a quantitative analysis of tumor number and volume displayed wide variation between individual Pas1/ + mice, and there was over a tenfold reduction in the aggregate tumor number and volume for the whole group of ASB mice compared to AB mice. This ®nding predicted the presence of at least one pulmonary adenoma resistance (Par) locus contributed by M. spretus, and allowed the mapping of Par1, on chromosome 11 (Manenti et al., 1996) . Through analogous breeding experiments between SWR and BALB/c strains, Par2 and Par4 on chromosomes 18 and 6, respectively, were mapped (Obata et al., 1996; Manenti et al., 1997) . Finally, a cross between resistant SM/J mice and strain A/J mice led to the identi®cation of Par3 on chromosome 12 (Pataer et al., 1997) . The genes implicated at the Par loci are currently unknown.
Another large group of genetic loci that modify the susceptibility to lung cancer (Sluc) in mice has been identi®ed by applying a multilocus mapping method to the analysis of F2 mice generated from recombinant congenic strains (RCS). The use of dierent RCS, which share a majority of the genome, reduces the complexity of the crosses and facilitates analysis. The multilocus method diers from the single quantitative trait loci (QTL) mapping technique that was used to identify the strong susceptibility locus Pas1 in that many loci are simultaneously analysed to identify loci which contribute either individually or collectively by virtue of complex genetic interactions to a particular trait. The multilocus method is, therefore, a more sensitive approach for the identi®cation of candidate genes in polygenic processes, including cancer. Consistent with the expected behavior of complex interactions in polygenic processes, interacting pairs of Sluc loci, such as Sluc1 and Sluc2, can increase or decrease the susceptibility of lung tumor formation, depending on the genetic background of the Sluc alleles (Fijneman et al., 1996) .
Conclusions and future directions
Investigations of murine lung cancer has led to the establishment of an in vivo screening assay for potential carcinogens and chemopreventative agents, the locus mapping of many modi®ers of lung tumorigenesis, and has revealed a tissue source for early pulmonary lesions. Lung tumors in mice contain many of the same molecular abnormalities as their human counterparts. However, the potential value of murine models in advancing our understanding of human lung cancer can only be realized after further analysis of existing models and the creation of new models.
First, genetically modi®ed mouse models must be improved. For example, although K-ras is the predominant form of ras present in pulmonary epithelial cells and is mutated in both human and murine lung cancer, mice expressing oncogenic K-ras have not been described. One approach would be to create a transgenic mouse that expresses an activated allele of murine K-ras under the control of a pulmonary epithelial cell speci®c promoter, and study this mouse alone and in crosses to mice de®cient for either p16
INK4a or p53. Indeed, a useful model for melanoma was created in this fashion (Chin et al., 1997) . Alternatively, Cre/LoxP technology could be used to create conditionally targeted alleles of genes known to be mutated in human lung cancer, such as Kras, p53, p16
INK4a and Rb (Sauer and Henderson, 1988 ). Mice with single or multiple conditional alleles can then be analysed following the cre-induced somatic cell gene activation of K-ras and inactivation of tumor suppressor genes. This approach should better mimic the human situation than current strains of mice, avoid the other life-limiting neoplasms common to mice with germline mutations in these tumor suppressor genes, and thus may allow the emergence of other histologic types and/or later stages of lung cancer in mice.
Second, the genes which modify murine pulmonary tumorigenesis need to be identi®ed. The importance of the characterization of the Pas, Par, and Sluc loci cannot be overstated because these studies cannot practically be done in man. Modi®er genes are likely important participants in human lung carcinogenesis since only a minority of smokers develop lung cancer, and several careful epidemiologic studies have demonstrated a correlation between microsatellite instability and an increased familial susceptibility to lung cancer in young nonsmokers (Ryberg et al., 1995; Suzuki et al., 1998) . The identi®cation of multiple single nucleotide polymorphic markers (SNPs) (Weiss, 1998) , the development of comparative genomic hybridization (CGH) methods (Donehower et al., 1995) , and sequencing of the mouse genome will collectively contribute towards this goal. In addition, more modi®er screens should be undertaken presently.
Third, as there is currently no eective early detection method for lung cancer, the mouse strains susceptible for the development of lung cancer should be vigorously examined for any early molecular, radiologic, or bronchoscopic characteristics which might be used for this purpose. For example, a gene expression analysis of the early lesions could identify molecular changes that would serve as the basis of a screening test.
Fourth, mice that develop lung cancer may facilitate the evaluation of novel therapeutic agents. For example, loci that modify lung cancer susceptibility, such as K-ras, would be appropriate targets to examine in susceptible mice by treating them with FPT inhibitors (Kohl et al., 1993) .
By beginning to address these shortcomings, the potential bene®t of attempting to model this devastating human disease in mice may be realized.
